What's Going On With Moleculin Biotech Stock Today?

Moleculin Biotech Inc MBRX announced that preclinical data regarding its next-generation anthracycline, Annamycin, was presented at the American Association for Cancer Research (AACR) Annual Meeting 2023.
The poster outlined results from the analysis of the pharmacokinetics of two formulations of Annamycin, liposome formulated drug product (L-ANN) and free Annamycin (ANN), in the liver in comparison with doxorubicin (DOX) and to determine its tumoricidal potential in a hepatocellular carcinoma (HCC) model in situ and experimental models of liver metastasis.
Related: Moleculin Reveals Final Topline Data From European Study Of Annamycin In Leukemia Setting.
ANN exhibited significantly higher accumulation in the liver parenchyma when compared to DOX (6-fold higher AUC values).
Researchers observed clear inhibition of the subcutaneous tumor growth after systemic (IV) administration of L-ANN.
Increased liver uptake of the drug directly affected the drug's activity in vivo.
An encouraging activity of L-ANN was observed in orthotopic models. Significant inhibition of the tumor growth and extension of the survival of L-ANN-treated mice vs. vehicle-receiving animals was observed.
L-ANN treatment resulted in an increase in survival in the CT26 colon cancer experimental metastasis animal model.
A significant delay in tumor progression was also observed in the pancreatic cancer liver metastasis model in a separate experiment.
MBRX shares have been volatile in trading, up 31% at one point before the circuit breaker halt.
Price Action: MBRX shares are down 6.35% at $0.88 on the last check Tuesday.

Market News and Data brought to you by Benzinga APIs

Comments

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga